An Open-label, Dose-finding, Phase Ib Study to Assess the Safety, Tolerability of JPI-547, a Dual Inhibitor of PARP/Tankyrase, in Combination With Modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in Patients With Locally Advanced and Metastatic Pancreatic Cancer
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Nesuparib (Primary) ; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Adverse reactions
- Sponsors Onconic Therapeutics
- 19 Feb 2025 Planned End Date changed from 1 Sep 2026 to 1 Jun 2026.
- 23 Jan 2025 Planned number of patients changed from 24 to 30.
- 23 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Sep 2026.